Review article: endpoints used in functional dyspepsia drug therapy trials: Review: dyspepsia endpoints for use in drug therapy trials
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The measurement of patient-reported outcomes (PRO) in treatment trials for functional gastrointestinal disorders is a matter of controversy. AIM: To focus on instruments and endpoints that have been used to evaluate the efficacy of therapeutic agents in functional dyspepsia (FD) trials, also considering the newly defined Rome III FD criteria. METHODS: A Medline search was conducted to identify relevant studies pertaining to FD treatment, with particular emphasis on the studies to date which have used validated outcome measures. RESULTS: Currently available outcome measures are heterogeneous across studies. They include global binary endpoints, analogue or categorical scoring scales, uni- or multi-dimensional disease specific questionnaires, global outcome evaluations and quality of life questionnaires. Across the available outcome measures, substantial heterogeneity is found, not only in the type of endpoint measure, but also in the number and types of symptoms that are considered to be part of the FD symptom complex. Especially based on content validity, none of the existing questionnaires or endpoints can be considered sufficiently validated to be recommended unequivocally as the primary outcome measure for FD trials according to the Rome III criteria. On the other hand, existing well-validated multi-dimensional questionnaires that include many non-FD symptoms can be narrowed down to evaluate only the cardinal symptoms according to Rome III. CONCLUSIONS: There is an urgent need to develop Rome III-based patient-reported outcomes for functional dyspepsia. Well-validated multi-dimensional questionnaires may serve as a guidance for this purpose, and could also be considered for use in ongoing clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jaeschke, R., Singer, J., & Guyatt, G. H. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90005-6 · Cited by 4,982
The MOS Short-form General Health Survey: Reliability and Validity in a Patient Population
Stewart, A. L., Hays, R. D., & Ware, J. E. (1988) · Medical Care · doi:10.1097/00005650-198807000-00007 · Cited by 3,339
Functional Gastroduodenal Disorders
Tack, J., Talley, N. J., Camilleri, M., Holtmann, G., Hu, P., Malagelada, J.-R., & Stanghellini, V. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.059 · Cited by 2,418
Self-citationA methodological framework for assessing health indices
Kirshner, B., & Guyatt, G. (1985) · Journal of Chronic Diseases · doi:10.1016/0021-9681(85)90005-0 · Cited by 1,538
Patrick, D. L., Drossman, D. A., Frederick, I. O., Dicesare, J., & Puder, K. L. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018831127942 · Cited by 761
Design of Treatment Trials for Functional Gastrointestinal Disorders
Irvine, E. J., Tack, J., Crowell, M. D., Gwee, K. A., Ke, M., Schmulson, M. J., Whitehead, W. E., & Spiegel, B. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.010 · Cited by 550
Self-citationResponsiveness and validity in health status measurement: a clarification
Guyatt, G. H., Deyo, R. A., Charlson, M., Levine, M. N., & Mitchell, A. (1989) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(89)90128-5 · Cited by 480 · cited 1×
“are likely to be more useful in quantifying changes in quality of life in FD therapeutic trials.(20) Disease specific instruments in FD can be unidimensional (evaluating gastrointestinal symptoms) or multidimensional (evaluating both gastrointestinal symptoms and other domains”
BackgroundA comparison of Likert and visual analogue scales for measuring change in function
Guyatt, G. H., Townsend, M., Berman, L. B., & Keller, J. L. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90080-4 · Cited by 456 · cited 2×
“tion and interpretation of the 7-point scale recommend its use in clinical trials.(18) The Likert scale is often incor-”
MethodRentz, A. M., Kahrilas, P., Stanghellini, V., Tack, J., Talley, N. J., De la loge, C., Trudeau, E., Dubois, D., & Revicki, D. A. (2004) · Quality of Life Research · doi:10.1007/s11136-004-9567-x · Cited by 406 · cited 3×
“GERD.(128) It is composed of 20 items in six subscales: heartburn ⁄ regurgitation (seven items), nausea ⁄ vomiting (three items), postprandial fullness ⁄ early satiety (four”
BackgroundMethodInfluentialSelf-citationDesign of Treatment Trials for Functional Gastrointestinal Disorders
Irvine, E. J., Whitehead, W. E., Chey, W. D., Matsueda, K., Shaw, M., Talley, N. J., & Veldhuyzen van Zanten, S. J. O. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.058 · Cited by 286
Self-citation
Cited by
Design of Treatment Trials for Functional Gastrointestinal Disorders
Irvine, E. J., Tack, J., Crowell, M. D., Gwee, K. A., Ke, M., Schmulson, M. J., Whitehead, W. E., & Spiegel, B. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.010 · Cited by 550
Self-citationRandomised clinical trial: rifaximin versus placebo for the treatment of functional dyspepsia
Tan, V. P. Y., Liu, K. S. H., Lam, F. Y. F., Hung, I. F. N., Yuen, M. F., & Leung, W. K. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13945 · Cited by 143
“Our study’s strength derives from its assessment of both overall treatment effect and individual clinically important symptoms.(25) In the absence of a regulatory guideline on the magnitude of active drug response rate over placebo to be considered clinically relevant, an expert group suggested 10–15% over placebo wou…”
BackgroundResultCarbone, F., De Buysscher, R., Van den Houte, K., Schol, J., Goelen, N., & Tack, J. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.03.023 · Cited by 55
Self-citationPreziosi, G., Raptis, D. A., Raeburn, A., Thiruppathy, K., Panicker, J., & Emmanuel, A. (2013) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e328361eaf8 · Cited by 51
Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
“In the assessment of treatment outcomes in functional GI disorders such as irritable bowel syndrome (28), the US Food and Drug Administration (FDA) and European Medicine Agency (EMA) have mandated the use of validated questionnaires.”
Self-citation
Metadata
- Authors
- Ang, D., Talley, N. J., Simren, M., Janssen, P., Boeckxstaens, G., & Tack, J.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2011-01-12
- Volume
- 33
- Issue
- 6
- Pages
- 634-649
- ISSN
- 0269-2813 (ISSN-L)
- OpenAlex
- W1583262072
- Cited by
- 77
- References
- 13
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review article: endpoints used in functional dyspepsia drug therapy trials: Review: dyspepsia endpoints for use in drug therapy trials. https://app.cochat.ai/papers/10.1111/j.1365-2036.2010.04566.x
- The paper
- Ang, D., Talley, N. J., Simren, M., Janssen, P., Boeckxstaens, G., & Tack, J. (2011). Review article: endpoints used in functional dyspepsia drug therapy trials: Review: dyspepsia endpoints for use in drug therapy trials. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2010.04566.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.